Company news
PepGen Inc. news in 2023
PepGen Inc.'s news releases, calls and decks from 2023, newest first.
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
December 17, 2023
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
November 14, 2023
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
November 7, 2023
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
October 11, 2023
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
September 26, 2023
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
September 5, 2023
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
September 5, 2023
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
August 7, 2023
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
June 12, 2023
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
May 29, 2023
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
May 17, 2023
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments
May 10, 2023
PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference
May 3, 2023
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting
April 16, 2023
PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments
March 22, 2023
PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference
March 21, 2023
PepGen to Participate in the Stifel 2023 CNS Days Conference
March 20, 2023
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
March 15, 2023
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
March 12, 2023
PepGen to Participate in the SVB Securities Global Biopharma Conference
February 8, 2023
Decks in 2023
- Investor Presentation (March 2023)
Investor deck · 63 slides · Mar 27, 2023